n (%) | |
---|---|
No. of procedures | 38 |
Median age (years) | 51 (range 31–83) |
cT-stage prior to NST | |
Tis | 1 (2.6) |
1 | 4 (10.5) |
2 | 23 (60.5) |
3 | 6 (15.8) |
4 | 4 (10.5) |
cN-stage prior to NST | |
1 | 23 (60.5) |
2 | 9 (23.7) |
3 | 6 (15.8) |
Axillary lymph node stage on pretreatment PET/CT | |
cN<4 (< 4 18F-FDG-avid nodes) | 26 (68.4) |
1 | 10 |
2 | 14 |
3 | 2 |
cN4+ (≥ 4 18F-FDG-avid nodes) | 12 (31.6) |
Tumor histology | |
Ductal carcinoma in situ | 1 (2.6) |
Ductal carcinoma | 33 (86.8) |
Lobular carcinoma | 3 (7.9) |
Other | 1 (2.6) |
Receptor status | |
HR-positive/HER2-negative | 28 (73.7) |
Triple negative | 6 (15.8) |
HER2-positive | 4 (10.5) |
NST regimen | |
ddAC | 7 (18.4) |
ddAC + paclitaxel | 21 (55.3) |
ddAC + CP | 3 (7.9) |
CP | 2 (5.3) |
PTC-P | 3 (7.9) |
Endocrine | 2 (5.3) |